A/Prof Jeffrey Goh

MBBS (Monash), FRACP
Medical Oncologist
Become a Patient

A/Prof Jeffrey Goh is committed to achieving the best possible outcomes for his patients. He combines an active interest in research and clinical trials with an empathetic approach to care, to support the physical and emotional needs of his patients throughout their cancer journey.


A/Prof Jeffrey Goh is an experienced medical oncologist and Adjunct Professor at Queensland University of Technology (QUT). He consults and treats patients at Icon Cancer Centre Chermside and Icon Cancer Centre Greenslopes. In 1996 he completed his Bachelor of Medicine, Bachelor of Surgery (MBBS) at Monash University and moved to Adelaide for his residency. He subsequently moved from Adelaide to Brisbane to establish his specialist career, initially working at Greenslopes Private Hospital as a haematology & oncology registrar in 2002. A/Prof Goh subsequently held a position as a laboratory and clinical haematology registrar at the Princess Alexandra Hospital in 2003. He completed his three years of advanced specialist medical oncology training in Brisbane and became a Fellow of the Royal Australasian College of Physicians (FRACP) in 2007.

He represented the Queensland Medical Oncology Advanced Trainees within the Medical Oncology Group of Australia (MOGA) in 2007 prior to his appointment as staff medical oncologist at Royal Brisbane & Women’s Hospital (RBWH) in December 2008. A/Prof Goh commenced sessional private medical oncology practice as a Visiting Medical Officer (VMO) at Greenslopes Private Hospital (GPH) in 2008 and at Icon Cancer Centre Chermside in early 2010. He maintains a significant part-time role as senior staff specialist at RBWH.

A/Prof Goh is actively involved in numerous clinical trials and acted as principal investigator (PI) in a number of phase I/Ib, II and III gynaecological oncology, urological malignancy and early phase drug trials at RBWH, Icon and GPH. He is also a co-investigator in numerous other multi-centre clinical trials in oncology. A/Prof Goh maintains an active interest in clinical research and is a member of several leading cancer trial groups including the Australian and New Zealand Urogenital & Prostate Cancer Trials Group (ANZUP), American Society of Clinical Oncology (ASCO), International Gynecologic Cancer Society (IGCS) and European Society of Medical Oncology (ESMO). He was previously a Board Member and chair of the QA Committee of the Australia & New Zealand Gynaecological Oncology Group (ANZGOG) and is the current Chair of the Cervical Cancer Tumour Type Working Group of ANZGOG.

He is co-supervisor of PhD candidates at the University of Queensland and was previously a senior lecturer. A/Prof Goh is also involved with mentoring advanced trainee registrars in medical oncology at RBWH. Additionally, A/Prof Goh is a member of Icon’s Research Committee and Medical Advisory Committee (MAC). His clinical experience covers a broad range of solid tumour malignancies, with special clinical interest in gynaecological cancer, genitourinary cancer and colorectal cancers, in addition to phase I/Ib clinical trials.

Affiliations & Memberships

  • Adjunct Professor, Queensland University of Technology (QUT)
  • Australian & New Zealand Gynaecological Oncology Group (ANZGOG)
  • Australian and New Zealand Urogenital & Prostate Cancer Trials Group (ANZUP)
  • American Society of Clinical Oncology (ASCO)
  • European Society of Medical Oncology (ESMO)
  • International Gynecologic Cancer Society (IGCS)
  • Royal Australasian College of Physicians (RACP)

Special Interests

A/Prof Jeffrey Goh accepts referrals for all cancer types, with a special clinical interest in:
  • Colorectal cancer
  • Genitourinary cancer
  • Gynaecological cancer
  • Ovarian cancer
  • Prostate cancer

Icon Locations

Chermside View centre
Greenslopes View centre

Visiting Locations

  • Royal Brisbane and Women’s Hospital


  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Robert L Coleman, Amit M Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I Weberpals, Andrew Clamp, Giovanni Scambia, Alexandra Leary, Robert W Holloway, Margarita Amenedo Gancedo, Peter C Fong, Jeffrey C Goh, David M O’Malley, Deborah K Armstrong, Jesus Garcia-Donas, Elizabeth M Swisher, Anne Floquet, Gottfried E Konecny, Iain A McNeish, Clare L Scott, Terri Cameron, Lara Maloney, Jeff Isaacson, Sandra Goble, Caroline Grace, Thomas C Harding, Mitch Raponi, James Sun, Kevin K Lin, Heidi Giordano, Jonathan A Ledermann. The Lancet, 2017; 390(10106):1949-1961. 


  • Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial (CAN-003). J. Gray, B. Benigno, J. Berek, J. Chang, J. Mason, L. Mileshkin, P. Mitchell, M. Moradi, F. O. Recio, C. M. Michener, A. Alvarez Secord, N E. Tchabo, J. K. Chan, J. Young, H. Kohrt, S. E. Gargosky and J.C. Goh. Journal for ImmunoTherapy of Cancer, 2016; 4:34.

  • Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. T.K. Choueiri, T. Powles, M. Burotto, B. Escudier, M.T. Bourlon, B. Zurawski, V.M. Oyervides Juárez, J.J. Hsieh, U. Basso, A.Y. Shah, C. Suárez, A. Hamzaj, et al. The New England Journal of Medicine, 2021; 384: 829-841. 

  • Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. R. Motzer, B. Alekseev, S-Y. Rha, C. Porta, M. Eto, T. Powles, V. Grünwald, T.E. Hutson, E. Kopyltsov, M.J. Méndez-Vidal, V. Kozlov, A. Alyasova, et al. The New England Journal of Medicine, 2021; 384: 1289-1300. 

  • [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. E.D Sternberg, J. Cook, L.P Ahoua Alou, S. B. Assi, A.A Koffi, D.T. Doudou, C.J. Aoura, R.Z. Wolie, M.S. Welbeck, A. Oumbouke, E. Worrall, I. Kleinschmidt, R. N’Guessan, M.B. Thomas. The Lancet, 2021; 397(10276): 805-815.